skip to main content

    Updated Visitor Guidelines

 

MENU

 

Chronic Leukemia

U-M Rogel Cancer Center first in Michigan to offer all FDA approved CAR T-cell therapies

Media contact: Jessica Webster-Sendra, 734-764-2220 |  Patients may contact Cancer AnswerLine, 800-865-1125

ANN ARBOR, Michigan — With the recently announced FDA approval of Kymriah to treat adults with lymphoma, the University of Michigan Rogel Cancer Center is the first center in Michigan to offer all currently available CAR T-cell therapies.

Panel predicts whether rare leukemia will respond to treatment

Patients with chronic myelomonocytic leukemia have limited treatment options, and those that exist are effective only in fewer than half of patients. Now, a new study identifies a panel of genetic markers that predicted which tumor samples would likely respond to treatment.